In March 2026, the American Heart Association, the American College of Cardiology, and nine partnering medical societies released updated guidelines for managing high cholesterol to prevent heart attacks and strokes. The changes are significant: a new study published in JAMA on July 20 found that the updated recommendations now make approximately 87.5 million U.S. adults eligible for statin therapy -- that is 56.6% of adults between ages 30 and 79, and 21.5 million more people than were eligible under the previous guidelines.
For context: that is more than one in every two adults in the country being recommended a daily cholesterol-lowering drug.
What changed in the 2026 guidelines.
The previous guidelines focused on adults ages 40 to 75 and estimated cardiovascular risk over a 10-year window. The new guidelines make two significant shifts. First, they expand the age range to 30-79, pulling younger adults into the conversation earlier. Second, and more consequentially, they extend the risk horizon from 10 years to 30 years.
That second change is what drives the majority of the newly eligible population. Under the new model, a person in their 30s or 40s with a low short-term cardiovascular risk can still qualify for a statin if their estimated 30-year risk of a cardiovascular event reaches 10% or more. The guidelines also now recommend measuring lipoprotein(a) at least once in a person's lifetime to screen for inherited cardiovascular risk -- a change from previous versions.
A new risk calculator, the PREVENT-ASCVD tool, replaces the older Pooled Cohort Equations used in prior guidelines and is designed to give a more personalized estimate of risk.
The science behind the shift is real
Dr. Timothy S. Anderson, M.D., M.A.S., primary care physician and assistant professor of medicine at the University of Pittsburgh and a member of the committee that wrote the new guidelines, was direct about what the evidence does and does not show.
"Observational evidence suggests the longer people are exposed to high levels of inflammatory cholesterol molecules, the greater their downstream risks of heart attacks and strokes are," Anderson said. "Unfortunately, we do not have randomized clinical trials for low-risk people 30 years out that would directly support this new understanding of how risk builds more gradually over the years, because such trials are expensive, and we need to wait decades for the answer."
In other words: the rationale for treating low-risk younger adults with statins is based on observational data and biological plausibility, not long-term controlled trials. The guidelines acknowledge this, and Anderson is candid about it.
Statins carry real side effects, and muscle damage is the most common.
Statins are among the most widely prescribed drugs in the world and have a well-established safety record for high-risk patients. But at population scale, their side effect profile matters. Research published in The Lancet found that 10-15% of statin users report muscle-related symptoms, ranging from mild aches to more significant weakness. A 2021 review in PubMed (PMID: 35955495) documented that statins can cause myalgia, cramps, immune-mediated necrotizing myopathy, and in rare cases rhabdomyolysis -- a breakdown of muscle tissue that can lead to kidney damage. Additional neurological effects, including peripheral neuropathy, have also been reported.
Serious adverse events remain rare, but "rare" changes meaning when 87 million people are taking a drug. An additional 21.5 million people entering statin therapy means the absolute number of people experiencing side effects, even at a low percentage, will be substantial.
The doctor who helped write the guidelines says lifestyle still comes first.
This is the part that tends to get lost in the coverage of expanded eligibility. Anderson is explicit: "It's certainly very reasonable that many people will talk about this with their doctor and say, 'Okay, what can I do that does not involve medication?'" Physicians will continue to recommend lifestyle changes - diet, exercise, weight management, smoking cessation - to all patients regardless of cholesterol levels.
Eligibility under the new guidelines does not mean a mandate. Anderson frames the decision for lower-risk, younger patients as "preference-based" - one that should weigh potential cardiovascular risk reduction against side effects, cost, and a patient's own values. "Ultimately, in this grey zone, patients should talk to doctors," he said.
The Animal Base Perspective: Food Over Pharmaceuticals
As guidelines expand to label tens of millions of healthy Americans as candidates for preventative medication, the mainstream approach to cardiovascular risk remains hyper-focused on lowering numbers through drugs. At Animal Base, we advocate for addressing the root cause of metabolic health through targeted, real-food nutrition. Contrary to outdated dietary dogma, high-quality red meat is not the antagonist in heart health. Instead, it is a vital source of bioavailability and human nutrition. When you eliminate refined carbohydrates and industrial seed oils in favor of whole, animal-based foods, the body naturally supports optimal lipid profiles and metabolic function. Before young, otherwise healthy individuals default to a daily statin prescription, looking closely at nutrition standard offer a powerful, drug-free alternative.
